Capricor Therapeutics, Inc. (CAPR): Sinai Medical Center Cedars , 10% owner of Capricor Therapeutics, Inc. purchased 312,500 shares on Sep 21, 2016. The Insider buying transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.20 per share for a total value of $1,000,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 21, 2016, Sinai Medical Center Cedars (10% owner) purchased 416,666 shares at $2.40 per share price.On Mar 21, 2016, Linda Marban (CEO) purchased 10,152 shares at $2.40 per share price.Also, On Mar 21, 2016, Anthony Bergmann (Vice President of Finance) purchased 2,030 shares at $2.40 per share price.On Aug 21, 2015, Louis J Grasmick (director) purchased 11,900 shares at $4.15 per share price.
Capricor Therapeutics Inc: On Thursday, Sep 22, 2016 heightened volatility was witnessed in Capricor Therapeutics Inc which led to swings in the share price. The shares opened for trading at $3.56 and hit $3.63 on the upside , eventually ending the session at $3.63, with a gain of 1.81% or 0.0644 points. The heightened volatility saw the trading volume jump to 20,057 shares. The 52-week high of the share price is $5.4 and the company has a market cap of $65 M . The 52-week low of the share price is at $1.88.
Company has been under the radar of several Street Analysts.Capricor Therapeutics Inc is Resumed by H.C. Wainwright to Buy and the brokerage firm has set the Price Target at $13. The Rating was issued on Jul 6, 2016.
Capricor Therapeutics Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development which include CAP-1002 CAP-1001 CSps Exosomes Cenderitide (CD-NP) and CU-NP. The Company’s technology is based in cardiospheres (CSps) which are multi-cell clusters of cardiac derived cells. The Company’s product candidate the cardiosphere-derived cells (CDC) is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).